Weight loss drugs not a threat to Nestle biz: CEO Mark Schneider

Nestle CEO Mark Schneider has defended its strategy of building a lower-calorie product portfolio, stating that the threat of GLP-1 weight-loss drugs is less significant. The company now generates half of its revenue from coffee, pet care, and vitamins, a shift from 30% seven years ago. Schneider expects the vitamins, minerals, and supplements business to grow in the mid- to high-single digits.